Key Metrics of AxoGen
Revenue$159M▲ 14.7% YoYFY 2023
Operating income−$21.5M▲ 27.8% YoY
Net profit−$21.7M▲ 25.0% YoY
Shareholders' equity$95.7M
Market cap$2.2BAXGN · $36.68
Competitors10identified
About AxoGen
Sectors
Company details
- Website
- axogeninc.com
- Listed
- Nasdaq: AXGN
Operational Areas of AxoGen
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameAxogen Inc.
TickerAXGN
ExchangeNasdaq
CountryUnited States
SEC CIK0000805928
Listed since—
IndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://www.axogeninc.com
US market & SEC filings
AXGN · Nasdaq · SEC CIK 0000805928
Last price · 25 Oct 2026
$36.68
+0.55%
Market cap$2.2B
P/E—On FY 2023 diluted EPS
Volume961,658
SectorHealth CareBiotechnology: Electromedical & Electrotherapeutic Apparatus
Country · IPOUnited States
AXGN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeAlachua
GSTIN—
Email—
Websitehttp://www.axogeninc.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of AxoGen
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology
Filings
No filings on record yet.